SCHEMBL6678166

SCHEMBL6678166

CC(C)(C)OC(=O)NC1(c2cccc(N)c2)CCC1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.39
AKT2 P31751 1/20 0.39
CNR1 P21554 2/20 0.36
CNR2 P34972 2/20 0.36
KIT P10721 1/20 0.36
CTSD P07339 5/20 0.36
BACE1 P56817 4/20 0.36
GHSR Q92847 1/20 0.34
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
SSTR4 P31391 1/20 0.34
ITGB1 P05556 1/20 0.34
ITGA4 P13612 1/20 0.34
ITGB7 P26010 1/20 0.34
PPIA P62937 2/20 0.33
ALDH1A1 P00352 2/20 0.33
NR1H2 P55055 1/20 0.33
CYP2C19 P33261 1/20 0.33
SCN9A Q15858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6681079 0.97 AKT1 (0.37) AKT1AKT2CNR1CNR2KIT
SCHEMBL6676765 0.96 SSTR4 (0.38) AKT1AKT2CNR1CNR2KIT
SCHEMBL6680422 0.95 AKT1 (0.39) AKT1AKT2CNR1CNR2KIT
SCHEMBL30749325 0.85 AKT1 (0.43) AKT1AKT2CNR1CNR2KIT
SCHEMBL12134686 0.84 AKT1 (0.41) AKT1AKT2CNR1CNR2SSTR4
SCHEMBL17040898 0.84 SSTR4 (0.47) AKT1AKT2CNR1CNR2SSTR4
SCHEMBL31237008 0.84 AKT1 (0.40) AKT1AKT2CNR1CNR2KIT
SCHEMBL521485 0.84 HDAC3 (0.45) AKT1AKT2ALDH1A1SCN9A
SCHEMBL31237047 0.82 AKT1 (0.40) AKT1AKT2KITPPIAALDH1A1
SCHEMBL30749314 0.82 AKT1 (0.40) AKT1AKT2CNR1CNR2KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709712-A1 GSK3A INHIBITORS AND METHODS OF USE THEREOF Blueprint Medicines Corporation (US) 2026-03-18 EP disclosed
WO-2025024030-A2 MOLECULAR GLUES TARGETING A TRANSCRIPTIONAL REGULATOR OF ABERRANT METABOLIC STATES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-01-30 WO disclosed
WO-2024233900-A1 GSK3A INHIBITORS AND METHODS OF USE THEREOF BLUEPRINT MEDICINES CORPORATION (US) 2024-11-14 WO disclosed
EP-0798292-B1 ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY CHUGAI SEIYAKUKABUSHIKI KAISHA (JP) 2004-11-03 EP disclosed
US-6534546-B1 Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-03-18 US disclosed
CN-1075808-C Aniline derivatives having nitric oxide synthase inhibitory activity CHUGAI PHARMACEUTICAL CO LTD (JP) 2001-12-05 CN disclosed
CN-1310169-A Anils with nitric oxide synzyme inhibiting function SHUGAI SEIYAKU K K (JP) 2001-08-29 CN disclosed
CN-1172473-A Aniline derivatives having nitric oxide synthase inhibitory activity CHUGAI PHARMACEUTICAL CO LTD (JP) 1998-02-04 CN disclosed
EP-0798292-A1 ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY Chugai Seiyaku Kabushiki Kaisha (JP) 1997-10-01 EP disclosed